Last reviewed · How we verify

NCT05210699

CSD201201: Study to Assess Elements of Abuse Liability for Electronic Nicotine Delivery System P12

Completed NA Last updated 29 June 2022
What this trial tests

NA trial testing Product A in Smoking in 36 participants. Completed in 17 May 2022.

Timeline
21 March 2022
Primary endpoint
17 May 2022
17 May 2022

Quick facts

Lead sponsorRAI Services Company
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposeother
Enrollment36
Start date21 March 2022
Primary completion17 May 2022
Estimated completion17 May 2022
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

RAI Services Company

Who can join

Adults 21 to 60, any sex, with Smoking or Smoking Behaviors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, open-label, 6-way crossover, multi-site study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics \[PD\]), and nicotine uptake (pharmacokinetics \[PK\]) during and following ad libitum use of the Electronic Nicotine Delivery Systems (ENDS) investigational products (IPs) in generally healthy combustible cigarette (CC) smokers and dual users of CC and ENDS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Product A

Trials testing the same drug.

Other recruiting trials for Smoking

Currently open trials in the same condition.

Other RAI Services Company trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05210699.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing